Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

25%

2 trials in Phase 3/4

Results Transparency

14%

1 of 7 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

Phase 3

2(33.3%)

Phase 2

2(33.3%)

Phase 1

2(33.3%)

6Total

Phase 3(2)

Phase 2(2)

Phase 1(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT07307794Phase 1Recruiting

To Evaluate the Adhesion of TK-254RX on Healthy Participants

Role: collaborator

NCT06866613Phase 3Completed

Phase III Trial to Evaluate the Efficacy and Safety in Patients With Ankle Sprains.

Role: collaborator

NCT06871046Phase 3Completed

Phase III Trial to Assess the Safety and Efficacy of TK-254RX in Patients With Contusions

Role: collaborator

NCT06042192Phase 1Completed

Open Label Trial to Evaluate the Adhesion of TK-254RX in Healthy Volunteers.

Role: collaborator

NCT04908748Phase 2Completed

Efficacy and Safety of Esflurbiprofen Hydrogel Patch in the Treatment of Local Acute Pain

Role: collaborator

NCT00561691Completed

Nimotuzumab in Children With Intrinsic Pontine Glioma

Role: collaborator

NCT00727324Phase 2Completed

Safety/Efficacy Study of Bovine Intestinal Alkaline Phosphatase in Patients With Moderate to Severe Ulcerative Colitis

Role: collaborator

NCT00561873Completed

Nimotuzumab in Children With HGG

Role: collaborator

All 8 trials loaded